Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Phase III randomized clinical trials in 1,405 participants with psoriatic arthritis evaluated guselkumab treatment through week 100. The stu…
Pain scores for psoriatic arthritis strongly predict long-term joint damage, giving doctors clear numbers to track real progress and adjust …
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
Guselkumab shows promise for ulcerative colitis in this early phase 3 trial.
This phase 3 randomized trial evaluated guselkumab in adults with moderately to severely active ulcerative colitis who had inadequate respon…
Patients with ulcerative colitis who failed other treatments achieved remission in a new trial using subcutaneous guselkumab injections.
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
Can a psoriasis drug help with a rare, hard-to-treat skin condition?
A case report and literature review describes a 48-year-old male with inverse psoriasis who showed marked improvement in cutaneous lesions a…
A single patient with hard-to-treat inverse psoriasis found marked relief in itching and skin lesions after just three injections of a newer…
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.